Sort by:

select Language:

Consolidated strategic information guidelines for viral hepatitis planning and tracking progress towards elimination: guidelines

World Health Organization WHO, (2019)

The document describes the use of strategic information at various stages of the response in the context of strengthening broader health information systems. Strategic information can be defined as data collected at all service delivery and administrative levels to inform policy and programme decisions.

Regional action plan for viral hepatitis in South-East Asia: 2016-2021

World Health Organization (WHO), Regional Office for South-East-Asia, (2016)

With the goal of ending viral hepatitis as a public health threat by 2030, the Regional Action Plan will provide an actionable framework for implementing evidence-based interventions at scale. It will be informed through strategic monitoring of the response, that must be equitable and sustainable and allow for innovations for acceleration and reaching out to all in need with health services. A major reduction in prices of newer drugs to potentially cure hepatitis C offers an added opportunity to work towards its elimination.

Stratégie mondiale du secteur de la santé contre l'hépatite virale 2016-2021: vers l'élimination de l'hépatite virale

Organisation mondiale de la Santé (OMS), (2016)

Le présent document énonce la première stratégie mondiale du secteur de la santé contre l’hépatite virale, une stratégie qui contribue à la réalisation du Programme de développement durable à l’horizon 2030.
Elle couvre les six premières années du plan d’action pour la santé de l’après-2015, c’est-à-dire la période 2016-2021, en s’appuyant sur le document Prévention et lutte contre l’hépatite virale : cadre pour l’action mondiale et sur deux résolutions relatives à l’hépatite virale adoptées par l’Assemblée mondiale de la Santé en 2010 et en 2014.
Cette stratégie porte sur les cinq virus de l’hépatite (les hépatites A, B, C, D et E), en mettant plus spécialement l’accent sur les hépatites B et C en raison de la lourde charge relative qu’elles représentent pour la santé publique.

Global health sector strategy on viral hepatitis 2016-2021: Towards ending viral hepatitis

World Health Organization (WHO), (2016)

This is the first global health sector strategy on viral hepatitis, a strategy that contributes to the achievement of the 2030 Agenda for Sustainable Development.
It covers the first six years of the post-2015 health agenda, 2016–2021, building on the Prevention and Control of Viral Hepatitis Infection: Framework for Global Action, and on two resolutions on viral hepatitis adopted by the World Health Assembly in 2010 and in 2014.
The strategy addresses all five hepatitis viruses (hepatitis A, B, C, D and E), with a particular focus on hepatitis B and C, owing to the relative public health burden they represent.

Epidémies d’hépatite E d’origine hydrique: identification, enquête et contrôle

Organisation mondiale de la Santé (OMS), (2014)

Rapport technique
Le présent manuel vise à fournir des informations concernant les méthodes d’enquête sur les épidémies d’hépatite E, et les mesures de prévention et de contrôle appropriées. De plus, le manuel fournit des informations relatives à l’agent responsable – appelé le Virus de l’hépatite E (VHE) – son épidémiologie, les manifestations cliniques de la maladie et le diagnostic.

Waterborne Outbreaks of Hepatitis E: recognition, investigation and control

World Health Organization (WHO), (2014)

Technical report
This manual aims to provide information about the methods for investigating outbreaks of hepatitis E, and measures for their prevention and control. In addition, the manual gives information about the causative agent – known as the hepatitis E virus (HEV) – its epidemiology, clinical manifestations of the disease and diagnosis.

Technology and Market Landscape Hepatitis C Medicines, August 2017

A.Hill, T. Swan and K.Timmermans , Eds.: World Health Organisation (WHO); UNITAID, (2017)

Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi- nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim- ited. Initially, due to their high prices, affordability of DAAs was limited in high-, middle- and low- income countries alike. Now there is a divide between those countries where, because of intellectual property barriers, prices have remained (very) high and other countries where generics are, or can be, available at much lower prices. The result is a dual market

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

European Association for the Study of the Liver, (2017)

J Hepatol (2017),

17 hits